{"pageContent": "Objective: It is estimated that 600,000 men are currently living in North America with castrate levels of testosterone as a result of androgen deprivation therapy for prostate cancer. The goal of this study was to explore how patients and their partners adjust to changes associated with androgen deprivation therapy (ADT).", "metaData": {"source": "Palliative hemibody irradiation in hormonally refractory metastatic prostate cancer\nhttps://pubmed.ncbi.nlm.nih.gov/2474883/"}}